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Omalizumab is a humanized murine monoclonal antibody directed toward a portion of the IgE
indicated in Europe for the treatment of severe persistent allergic asthma, inadequately
controlled despite high-dose of ICS (mean BDP equivalent dose of inhaled corticosteroid
2224.68 mg/die) in association with long-acting b2 agonists.
Our aim was to describe the experience, efficacy and safety in a cohort of Italian patients
treated with omalizumab in a real-life clinical setting. One hundred and forty two patients
from 13 Italian Centers were observed and analysed. The dosage of omalizumab was estab-
lished according to the labelling indication, with a median dose of IgE of 297.38 IU/ml or
kU/l. During the previous year, all patients experienced frequent exacerbations
(meanZ 4.87), emergency visits (meanZ 4.45) and hospitalisation (meanZ 1.53). Following
treatment with omalizumab, the annual rate of exacerbations, emergency visits ando di Medicina Interna, Universita` di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. Fax: þ39
iroma2.it (M. Cazzola).
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Experience of omalizumab 1411hospitalisation decreased by 79%, 88% and 95%, respectively. The proportion of patients
without exacerbation, not needing emergency visits and hospitalization increased by 610%,
154% and 28%, respectively. The response to omalizumab measured with the GETE (global eval-
uation of treatment effectiveness) scale rated as good to excellent in 77% of patients. Overall,
9.6% (nZ 9) of the patients experienced one single adverse effect. Only one patient reported
a serious adverse event (local reaction at the site of injection) leading to interruption of treat-
ment. The observed reduction of asthma-related events in particularly poorly controlled
patients in this Italian real-life setting is consistent with the results of other observational
studies.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Asthma is a disease that causes debilitating daily symptoms
and unexpected acute exacerbations of symptoms. Symp-
toms can seriously limit patients’ activities, absence from
work or school, hospitalization and visits to the emergency
department, and a reduced quality of life. The Global
Initiative For Asthma (GINA) (REF) describes four levels of
control. Patients with inadequately controlled asthma are
more at risk of associated morbidity and mortality.1
Severe asthma affects approximately 10% of all asthma
sufferers. This subset of patients has greater morbidity and
a disproportionate need for health care support compared
with the less severe subset.2
The recombinant humanized monoclonal anti-immuno-
globulin E (IgE) antibody omalizumab has recently been
approved as an add-on treatment for inadequately
controlled persistent allergic asthma (GINA step 5 therapy).
Omalizumab is directed against the receptor-binding
portion of the IgE immunoglobulin. Thanks to this mecha-
nism of action, it leads to a significant reduction in the
concentration of circulating free-IgE antibodies and, ulti-
mately, to a decreased binding with the cell surface
receptors preventing sensitisation of mast cells and baso-
philes, thus interrupting the inflammatory cascade involved
in the pathogenesis of allergic asthma. Furthermore, the
risk of anaphylactic reaction is minimized since omalizu-
mab cannot interact with IgE molecules already bound to
cell surface receptors.3
The efficacy and safety of omalizumab have been eval-
uated in a large number of studies which have shown
a significant reduction in exacerbations of asthma, and
emergency visits. Furthermore, a significant improvement
in quality of life was observed in these patients with severe
persistent allergic asthma with a significant unmet need
despite best available therapy.4 Unfortunately, analyses of
patients treated in clinical trials have shown that it is
difficult to predict which patients, within the label char-
acteristics, will derive greatest benefit from omalizumab
based on their pre-treatment profile.5 Furthermore, the
typical clinical study patient with asthma represents a very
small proportion of the patient population being treated by
clinicians in everyday practice.6 Consequently, it is difficult
to predict the real impact of a long-term treatment with
omalizumab in every-day clinical practice, which can be
strongly influenced by local factors.
For this reason, we have conducted a prospective obser-
vational trial to evaluate the efficacy and tolerability ofomalizumab in a real-life setting, following the introduction
of the drug to the Italian market in January 2007. Our study
describes the characteristics of these patients and the real-
life effectiveness of omalizumab in the first large group of
patients who received this treatment in Italy.
Methods
Patients
This is an observational study conducted in compliance with
the Good Clinical Practice (GCP) standards and the decla-
ration of Helsinki and it was approved by the local Ethics
Committees. All patients included gave signed written
informed consent.
During the period between January 2007 and October
2008, 142 patients with uncontrolled severe persistent
allergic asthma were treated with omalizumab and were
prospectively investigated by 12 certified Italian Clinical
Centres (outpatient asthma clinics at University Hospitals
or General Hospitals). All patients were selected for
treatment with omalizumab according to clinical practice
on the basis of all six criteria for eligibility for the indica-
tion approved by the European Medicines Agency (EMEA)7:
age equal or over 12 years, moderate to severe persistent
allergic asthma (according to the definition stated by GINA
Guidelines), poor control of asthmatic disease (i.e.,
persistence of symptoms, emergency room visits, hospi-
talization the previous year), despite ongoing treatment
with high doses of inhaled corticosteroids (ICS) in associa-
tion with; long-acting b2 agonists (LABA), total serum IgE
between 30 and 700 IU/ml, and evidence of sensitization to
at least one perennial allergen (by prick test or RAST).
Characteristics of the study population are outlined in
Table 1.
Data collection
Data was collected at baseline, month 4, 8 and 12. We
report here the evaluation performed at the end of the
study (month 12). During the first study visit, physicians
collected demographic data (sex, age, etc.), current
asthma treatment (inhaled corticosteroids, oral cortico-
steroids, long-acting b2 agonists, sustained-release
theophylline, leukotriene receptors antagonists), pulmo-
nary function (FEV1), weight and IgE level, to assess oma-
lizumab dosing and dosing schedule, and data taken from
the year prior to starting omalizumab treatment about
Table 1 Study population.
Total population After 12-month
treatment
Patients 142 93
Age (years) 49.55 (4.08)
Sex [female] 72
Weight (kg) 70.32 (13.3)
Total IgE (IU/mL) 297.38 ( 200.90)
FEV1, % 64.82 (17.99)
FEV1, ml 1775.79 (660.24)
Leukotriene
receptor
antagonists
99 (69.7%) 43 (46.2%)
Slow-release
theophylline
21 (14.8%) 7 (7.5%)
Dose of inhaled
corticosteroid
(mg BDP
equivalent/day)
2224.68 (1837.31) 1604.62 (1456.95)
Mean monthly
dose of
omalizumab
411.94 (209.13)
1412 M. Cazzola et al.asthma-related events (number of exacerbations, hospi-
talization, emergency department visits). Data regarding
asthma-related treatment and asthma-related events were
also collected after 4, 8 and 12 months of treatment.
Furthermore, at these time-points date regarding safety
and adverse events were also collected. At months 8 and
12, a qualitative evaluation through the Global Evaluation
of Treatment Evaluation (GETE) questionnaire was also
performed (see Efficacy measure and statistical analysis).
Omalizumab treatment and concomitant
medications
The individual dose of omalizumab was calculated in
accordance with the dosing table, on the basis of patient’s
individual IgE load, i.e. on pre-treatment body weight and
total serum IgE level at screening, as previously described.8
Depending on the omalizumab overall dose, the drug was
administered by subcutaneous injection every 2 or 4 weeks.
During the treatment period, there were no restrictions on
the doses of ICS and LABA (taken separately or as a fixed
dose combination) and other concomitant asthma
medications.
Efficacy measures
The design of the trial is purely observational; hence we
neither defined a primary end-point nor performed
a statistical power calculation. The analysis is descriptive
and the efficacy of omalizumab in the patient population
observed is evaluated as reduction of uncontrolled asthma-
related events, i.e. exacerbations, emergency dept. visits,
hospitalization. Annual rates are calculated using patients-
years. Data description is based mainly on means and
standard deviation and analysis was performed using the
SAS software.Secondary efficacy evaluation was based upon responses
to the GETE Questionnaire. GETE is a five-point scale
assessment of asthma symptoms control, rating the
response to asthma treatment as ‘excellent’, ‘good’,
‘moderate’ and ‘poor’.9 The rating of symptoms control as
‘good’ or ‘excellent’ allows the patient to be defined as
a ’responder’. The evaluation was performed at the end of
the study period.
Results
Patients
During the period between January 2007 and October 2008,
we observed 142 patients with a diagnosis of uncontrolled
severe persistent asthma.
Mean (sd) age was 49.55 ( 14,8) years (range 14e77)
(Table 1). The median IgE level at baseline was 297.38
(IQR 121.5e431 IU/ml, range 31.5e805 IU/ml) and mean
body weight was 70.32 (13.30) kg. All patients were
sensitized to at least one perennial antigen, and were
treated with high doses of ICS. The mean pre-treatment
mean dose of inhaled corticosteroids (beclometasone
equivalent) was 2224.68 ( 1837.31, IQR 960e9000) mg/
die. 140 out of 142 patients were also treated with LABAs.
99 patients (69.7%) were taking anti-leukotriens agents
and 21 (14.8%) were taking slow-release teophilline. Oral
corticosteroids were taken by 52 out of 142 patients
(36.6%) as maintenance therapy. The mean dose of oma-
lizumab administered to patients was 411.94 mg/month
(range 60e750 mg/month).
Measurement of effectiveness
In the year prior to the starting the treatment with omali-
zumab, 123 out of 139 (88.5%) patients were suffering from
asthma exacerbations with a mean number of exacerba-
tion/patients/year of 4.87 (4.00), 89 out of 140 (63.6%)
asked for unscheduled healthcare utilisation/emergency
room visits, with a mean number of unscheduled cases of
medical assistance/emergency room/patients/year of 4.45
( 4.31), and 33 out of 141 (23%) were hospitalised, with
a mean number of hospitalization/patients/year of 1.53
(0.71) (Table 2).
Ninety-three out of 142 patients were treated for at
least 12 months. In this group of patients, the rate of
asthma exacerbations decreased to 18.3% (17 out of 93
patients) with a mean number of exacerbation/patients/
year of 1 (1.29), the number of unscheduled cases of
medical assistance/emergency room visits decreased to
7.6% (7 out of 92 patients) with a mean number of
unscheduled health care contacts/emergency room/year of
1.23 (0.49), and the number of hospitalizations decreased
to 1.1% (1 out of 93 patients with only one hospitalization;
Table 2).
Overall, following treatmentwithomalizumab, theannual
rate of exacerbations, emergency visits and hospitalisation
decreased by 78%, 87% and 96%, respectively (Fig. 1). The
proportion of patients without exacerbation increased by
610%, while patients with no emergency visit or hospitaliza-
tion increased by 154% and 28%, respectively (Fig. 2).
Table 2 Asthma-related events before and after 12-
month treatment.
Total population After 12-month
treatment
Asthma exacerbations Patients nZ 139 Patients nZ 93
YesZ 123 (88.5%) YesZ 17 (18.3%)
NoZ 16 (11.5%) NoZ 76 (81.7%)
Number of asthma
exacerbations/year
4.87 (4.00) 1 (1.29)
Hospitalizations Patients nZ 140 Patients nZ 92
YesZ 89 (63.6%) YesZ 7 (7.6%)
NoZ 51 (36.4%) NoZ 85 (92.3%)
Number of
hospitalizations/year
4.45 ( 4.31) 1.23 (0.49)
Unscheduled health
care
contacts/emergency
room visits
Patients nZ 141 Patients nZ 93
YesZ 33 (23%) YesZ 1 (1.1%)
NoZ 108 (77%) NoZ 92 (98.9%)
Number of
unscheduled
health care
contacts/emergency
room
visits/year
1.53 (0.71) N/A
Due to the observational design of the study, in a small number
of patients not all information are available.
Figure 2 Proportion of patients event-free during treatment
with omalizumab with respect to the previous year. Patients
treated with omalizumab for at least 4 months (nZ 130).
Exacerbation: þ610%, emergency visit: þ158%, hospitaliza-
tions: þ28%.
80%
100%
Experience of omalizumab 1413The rating performed though the GETE assessment was
excellent in 49% of patients and very good in other 28%
(Fig. 3).
In the 93 patients that were treated with omalizumab
for at least 12 months, the mean dose of inhaled cortico-
steroid decreased to 1604.62 (1456.95, IQR 640e2000) mg/
die (Fig. 4). Importantly, also the use of anti-leukotrienes,
theophylline, and oral corticosteroids decreased after 12-
month treatment with omalizumab (33.7%, 49%, and
71%, respectively) (Table 1 and Fig. 5).
Overall, 12 patients discontinued omalizumab treat-
ment, 4 within the first 4 months, 3 within 8 months and the
remaining 5 within 12 months. The main reason for
discontinuation was administrative issues raised by the
local health authorities as omalizumab reimbursement was
being discussed at that time (Table 3).Figure 1 Reduction in asthma-related events: proportion of
patient with at least one event during treatment with omali-
zumab with respect to the previous year. Patients treated with
omalizumab for at least 4 months (nZ 130): exacerbation:
78%, emergency visit: 87%, hospitalization: 96%.Overall, 6.7% (nZ 9) of patients experienced one
adverse effect. The most frequently reported adverse
effects were arthralgia (nZ 3), headache (nZ 2) and local
reaction at the site of injection (nZ 2). Only one patient
reported a serious adverse event (local reaction at point of
injection) and discontinued the treatment.
Discussion
Severe uncontrolled asthma is a condition with a high
burden of morbidity and mortality. Adequate control of0%
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Figure 3 Omalizumab effectiveness as evaluated with the
GETE Questionnaire.
Figure 4 Reduction of the mean use of inhaled corticoste-
roids in mg. Patients with a follow-up 5 months: previous
year: 2.2 mg, after treatment: 1.6 mg.
Table 3 Discontinuations of omalizumab treatment.
Discontinuations of treatment
Within 4 months 4
Within 8 months 3
Within 12 months 5
Reason for discontinuation
Unsatisfactory therapeutic effect 2
Patient’s wish 3
Adverse effect 1
Administrative issues 5
Due to the observational character of the study not all infor-
mation are available in a small number of patients.
1414 M. Cazzola et al.symptoms is often not achieved despite complex guideline-
driven therapy. Targeting the inflammatory and allergic
process, which triggers and maintains the condition of
airway inflammation, is shown to be an effective way of
controlling symptoms associated with severe allergic
asthma. Omalizumab is the first humanized monoclonal
antibody approved in Europe as an add-on therapy for
severe persistent uncontrolled allergic asthma. It targets
IgE molecules and binds to the Fc segment of the immu-
noglobulin, preventing interaction with the membrane cell
receptors on the surface of effector cells, ultimately pre-
venting the activation of the inflammatory cascade. The
efficacy of omalizumab in reducing severe asthma-related
exacerbation and emergency visits rates and in improving
the quality of life of patients with uncontrolled persistent
severe asthma has been demonstrated in a comprehensive
clinical program. Furthermore, in a recent review of the
use of omalizumab in the treatment of severe allergic
asthma, Holgate et al. 4 highlighted that also observational
studies have shown important benefits for many patients
with inadequately controlled severe persistent allergic
asthma responding to omalizumab therapy. This is an
important comment due to the fact that, in general, our
whole approach to the treatment of asthma is based on
guidelines. Nowadays, published guidelines are strictly
evidence-based and such evidence is graded for quality andFigure 5 Reduction of medication use. Patient with a follow-
up 5 months. OCS (Oral Corticosteroids): 71%, anti-leuko-
trienes: 33%, theophylline: 47%.strength of recommendation on the basis of specific criteria
such as trial design, method of analysis and relevance of
outcomes. The most relevant and strongest recommenda-
tions are those based on large, prospective, randomised
clinical trials.10
Nonetheless, the results of large randomised clinical
trials, enrolling a large number of carefully selected
patients, and providing highly statistically significant
outcomes for a drug, do not necessarily imply that the
results can be extrapolated to a larger, less selected
patient population6 as seen in everyday real-life clinical
practice. In fact, asthma is a heterogeneous disease with
a wide range of phenotypes; hence, it is not surprising that
many individuals with asthma are not eligible for rando-
mised clinical trials due to the protocol’s highly selective
inclusion and exclusion criteria. And this is truer for the
majority of patients with any co-morbid condition. Travers
et al. 11 found, perhaps not surprisingly, that only a small
percentage of their community patient type would have
met the entry criteria to be included in major asthma-
related randomised clinical trials. The percentage eligible
ranged from 0% to 36% but in most cases the figure was
10%. Notable among the reasons for ineligibility were lack
of bronchodilator reversibility, baseline FEV1 too low or too
high, lack of symptoms and/or bronchodilator use, not
currently requiring inhaled corticosteroids and a history of
>10 pack-years use of tobacco. The question also remains,
to what extent do strictly selected randomised trials really
provide information that justifies the choice and the cost of
therapy? The stricter the criteria, the easier it will be to
predict the outcome, and a sufficient number of patients
will, in most instances, secure enough power to reach
statistical significant differences.6
The importance of observational studies is clear in order
to evaluate the role and the benefit of innovative treat-
ments such as omalizumab in the real-life setting of asthma
management.
To date, three studies have explored this fundamental
issue. The first was a historic-prospective study performed
on patients having obtained a nominative temporary use
authorisation for omalizumab before the introduction of
the drug to the French market.12 The second was
a prospective post-marketing surveillance trial that evalu-
ated the efficacy and tolerability of omalizumab in a real-
life setting following the introduction of the drug to the
German market,13 and the third study was a prospective
Experience of omalizumab 1415multicenter “real-life” study conducted in Belgium, the
PERSIST study.14
In the first study, Molimard and co-workers obtained data
for 147 out of the 154 patients treated. 31.3% of patients
received inappropriate monthly doses of omalizumab (13
overdosed and 33 under-dosed). The authors concluded that
the results observed in this first real-life observation of the
use of omalizumab were comparable in terms of benefit to
those observed in randomized clinical trials. In fact the
analysis performed during the treatment period and
compared to the previous year, showed that patients with
a follow-up of at least 5 months experienced 62% fewer
exacerbations requiring oral corticosteroids, 65% fewer
emergency department visits and 29% fewer hospitalisations
per year. The biggest potential limit for the therapeutic
effect of omalizumab in clinical practice, as underlined by
the authors, was represented by under-dosing. Of the 28
patients (19%) who discontinued for unsatisfactory thera-
peutic effect, 7 were treated for less than the 16 weeks
recommended to evaluate efficacy, and 9 who were treated
for a longer period of time, were under-dosed.
Korn and co-workers 13 reported the results of the
observation of 280 patients who met the EU criteria for
add-on therapy with anti-IgE and were treated prospec-
tively with omalizumab by 134 physicians as part of
a German post-marketing surveillance trial, and were fol-
lowed-up for 6 months. The median follow-up time was 195
days, the patients were treated with a median dose of
450 mg omalizumab every 4 weeks. After 6 months,
a marked effect of omalizumab treatment was observed on
daily (76%) and nocturnal symptoms (84%), exacerba-
tions (82%), unscheduled medical assistance (81%),
hospitalizations (78%) and quality of life (Mini-AQLQ:
score increase from 2.9 to 4.5). Overall, efficacy of omali-
zumab was rated as excellent or good by the majority of
physicians (82%) and patients (86%).
In the PERSIST Study Brusselle and co-workers evaluated
the 15- and 52-week effectiveness of add-on omalizumab
treatment in 158 enrolled subjects, with poorly controlled
asthma despite treatment with inhaled corticosteroids and
long-acting b-agonists and who experienced exacerbations
during the previous year. After 16 weeks of therapy, a good/
excellent GETE was achieved by >82% (p< 0.001), the total
AQLQ scores improved in >82% by  0.5 points (p< 0.001)
and >91% of the subjects were exacerbation -free. At 52
weeks, the same results were achieved by>72% (p< 0.001),
> 84% (p< 0.001) and >65% (p< 0.001), respectively. In
addition, a significant reduction in healthcare utilization
compared the year prior to treatment was observed.
Finally, a small questionnaire-based observational study
in 65 patients in the UK, who had continued with omalizu-
mab therapy beyond 16 weeks, by Niven et al.15 found that
out of 33 patients taking oral corticosteroid at baseline, 18
(54.5%) had reduced their oral corticosteroid and 8 (24.2%)
had stopped oral corticosteroid altogether. The mean
relative reduction in oral corticosteroid dose from baseline
was 49% (22.6e11.6 mg, prednisolone equivalent).
Although these studies have been conducted in different
countries, where health regulations and clinical practice are
sometimes different, they all confirm the usefulness of oma-
lizumab in the treatment of severe asthma, in the real-life
setting, outside of strictly selected randomized clinical trials.Our study reports the results of a real-life experience
with omalizumab in 12 Italian Centres. The first important
aspect of our study is the fact that we have evaluated only
patients treated for up to one year. In the French study,
results came from patients with follow-up data at 5
months, whereas in the German study, the median follow-
up time was 195 days.
In our study, at the end of a 12-month period of treat-
ment with omalizumab, the annual rate of exacerbations,
emergency visits and hospitalisation decreased by 78%, 87%
and by 96%, respectively. Whereas in the French study, for
patients with follow-up data at 5 months or longer, the
annual rate of exacerbations decreased by 62%, emergency
visits by 65% and hospitalisations by 29%. In the German
study after 6-month follow-up the rate of asthma exacer-
bations, unscheduled medical assistance/emergency room
visits, and hospitalization decreased to 18.3% (44 out of 241
patients), 19.9% (48 of 241 patients), and 2.5% (12 out of
241 patients) respectively. In our study we observed, after
a 12-month treatment, a reduction in the rate of asthma
exacerbations, unscheduled medical assistance/emergency
room visits and hospitalization of 18.3% (17 out of 93
patients), 7.6% (7 out of 92 patients), and 1.1% (1 out of 93
patient) respectively, showing overall improved outcomes
compared to the other two observational studies.
Admittedly a limit of this analysis is that the rate of
exacerbations, emergency visits and hospitalizations in the
year before the study were collected retrospectively and
this could have induced a bias. This would mainly be in
exacerbations as the investigators might not have recorded
each patient’s medical history and therefore some infor-
mation might have been missed.
However we must consider that the patients were very
closely monitored before the study due to the severity of
their illness and it seems more likely that if there had been
any inaccuracy, this would have been an underestimation
rather than an overestimation.
Only 12 out of 142 (8.5%) of our patients discontinued
omalizumab treatment, similar to the Belgian study
(nZ 19, 12%), while both in the French study (nZ 45,
30.6%) and in the German study (nZ 91, 32.5%) nearly one
third of patients discontinued treatment. The main reason
for this was administrative, whereas in both the French and
the German study it was due to an unsatisfactory thera-
peutic effect. In our study, 6.7% (nZ 9) of patients expe-
rienced one adverse effect and in only one single patient
was this effect severe, leading to discontinuation. In the
French study, overall 26.5% (nZ 39) of the patients having
received omalizumab experienced at least one adverse
effect, five of which were severe, and in two cases led to
treatment discontinuation. In the German study a total of
198 adverse events in 100 patients (35.7%) and a total of
145 severe adverse events (73.2%) in 67 patients (23.9%)
were reported. In only 7 of all patients (2.5%) 33 adverse
events (16.7% of all adverse events) were considered to be
related to omalizumab treatment. In the PERSIST study
overall 55,6% (nZ 89) experienced at least one adverse
event. 12 patients (7.5%) had severe AEs suspected to be
related to omalizumab.
It is difficult to explain the difference in the therapeutic
outcomes observed in our study compared to what has been
reported elsewhere. It is possible that the more stringent
1416 M. Cazzola et al.criteria for inclusion in the treatment and/or full adher-
ence to the dosage as required by health authorities could
explain the discrepancies.15 In the French study, not all
patients fell within the range of the dosing table that
considers total IgE concentration and patients’ body
weight; in addition to that, several of them were treated
for less than 16 weeks and/or under-dosed. In the German
study, 14.9% of patients who were treated did not fall
within the range of the recommended dosing table that
considers total IgE concentration and body weight. In fact,
for these patients the IgE load was outside the recom-
mended dosing table.
In conclusion, our 12-month observational study, con-
ducted in a real-life setting, confirms that omalizumab is
effective and safe as an add-on treatment for uncontrolled
severe allergic persistent asthma. It has been shown to
reduce the incidence of uncontrolled asthma-related
events, such as exacerbations, unscheduled emergency
room visits and hospitalization, also in patients not
specifically selected for inclusion in a clinical trial, and can
be conveniently administered in every-day practice.
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